Literature DB >> 8997399

Angiotensin II-receptor stimulation of cytosolic calcium concentration in cultured renal resistance arterioles.

Z Zhu1, W J Arendshorst.   

Abstract

This study provides an initial characterization of basic morphological properties of cultures of vascular smooth muscle cells (VSMC) from rat preglomerular resistance vessels and of the functional coupling of angiotensin II (ANG II) receptors to cytosolic free calcium concentration ([Ca2+]i (fura 2 fluorescence photometry). Renal VSMC were isolated from interlobular arteries and afferent arterioles (< 50 microns) using an iron oxide sieving method and compared with rat aortic VSMC cultured under similar conditions. Quiescent monolayers maintained uniform morphology and [Ca2+]i signaling profile between passages 3 and 10. Arteriolar and aortic VSMC were spindle shaped and expressed smooth muscle-specific alpha-actin and myosin heavy chains SM-1 and SM-2. ANG II caused a rapid increase in [Ca2+]i, followed by a sustained plateau phase at 50-60% of the peak value. The initial maximum [Ca2+]i responses were dose dependent and of similar magnitude in renal arteriolar and aortic VSMC. ANG II (10(-7) M) increased [Ca2+]i from 50 to 240 nM in arteriolar and from 57 to 201 nM in aortic VSMC (P < 0.001 for both). Inhibition of ANG II effects on [Ca2+]i revealed significant signaling through distinct AT-receptor subtypes (losartan and PD-123319 sensitive) in renal arteriolar VSMC. In contrast, only losartan was effective in aortic VSMC. The AT2-receptor ligand CGP-42112 had no effect in either vessel type. Our results demonstrate that cultured arteriolar VSMC have anatomical similarities to aortic VSMC and functional differences in AT-receptor signaling in response to ANG II. This novel preparation should provide a useful approach with which to investigate cellular mechanisms concerning receptor coupling to signaling pathways involved in vascular reactivity of arteriolar VSMC in the microcirculation in general and the kidney in particular.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8997399     DOI: 10.1152/ajprenal.1996.271.6.F1239

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

1.  The subtype 2 of angiotensin II receptors and pressure-natriuresis in adult rat kidneys.

Authors:  K L Liu; M Lo; E Grouzmann; M Mutter; J Sassard
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

2.  Phenotypic modulation of cultured vascular smooth muscle cells: a functional analysis focusing on MLC and ERK1/2 phosphorylation.

Authors:  M A Carrillo-Sepúlveda; M L M Barreto-Chaves
Journal:  Mol Cell Biochem       Date:  2010-04-18       Impact factor: 3.396

3.  AT1 receptor-activated signaling mediates angiotensin IV-induced renal cortical vasoconstriction in rats.

Authors:  Xiao C Li; Duncan J Campbell; Mitsuru Ohishi; Shao Yuan; Jia L Zhuo
Journal:  Am J Physiol Renal Physiol       Date:  2005-12-27

4.  Thyroid hormone stimulates NO production via activation of the PI3K/Akt pathway in vascular myocytes.

Authors:  Maria Alícia Carrillo-Sepúlveda; Graziela S Ceravolo; Zuleica Bruno Fortes; Maria Helena Carvalho; Rita C Tostes; Francisco R Laurindo; R Clinton Webb; Maria Luiza M Barreto-Chaves
Journal:  Cardiovasc Res       Date:  2009-09-04       Impact factor: 10.787

5.  Rho-kinase inhibition reduces pressure-mediated autoregulatory adjustments in afferent arteriolar diameter.

Authors:  Edward W Inscho; Anthony K Cook; R Clinton Webb; Li-Ming Jin
Journal:  Am J Physiol Renal Physiol       Date:  2009-01-07

6.  Type I inositol 1, 4, 5-triphosphate receptors increase in kidney of mice with fulminant hepatic failure.

Authors:  Ying Wen; Wei Cui; Pei Liu
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

7.  Tumor necrosis factor-alpha-induced reduction of glomerular filtration rate in rats with fulminant hepatic failure.

Authors:  Jing-Bo Wang; Dong-Lei Wang; Hai-Tao Wang; Zhao-Han Wang; Ying Wen; Cui-Ming Sun; Yi-Tong Zhao; Jian Wu; Pei Liu
Journal:  Lab Invest       Date:  2014-06-02       Impact factor: 5.662

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.